help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciaraldi, T. P.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciaraldi, T. P.
Right arrow Articles by Henry, R. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUCOSE
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 12 5838-5847
Copyright © 2001 by The Endocrine Society


Other Original Articles

Effects of the Long-Acting Insulin Analog Insulin Glargine on Cultured Human Skeletal Muscle Cells: Comparisons to Insulin and IGF-I

T. P. Ciaraldi, L. Carter, G. Seipke, S. Mudaliar and R. R. Henry

Veterans Affairs San Diego HealthCare System (9111G) and Department of Medicine, University of California-San Diego (T.P.C., L.C., S.M., R.R.H.), La Jolla, California 92093; and Aventis Pharm (G.S.), D-65926 Frankfurt, Germany

Address all correspondence and requests for reprints to: T. P. Ciaraldi, Ph.D., Department of Medicine (9111G), University of California-San Diego, La Jolla, California 92093. E-mail: tciaraldi{at}ucsd.edu

Abstract

The aim of this study was to determine whether the long-acting insulin analog, insulin glargine, behaves like human insulin for metabolic and mitogenic responses in differentiated cultured human skeletal muscle cells from nondiabetic and diabetic subjects. Human insulin and insulin glargine were equipotent in their ability to compete for [125I]insulin binding. Insulin glargine displaced [125I]IGF-I from the IGF-I-binding site with approximately 0.5% the potency of IGF-I. In nondiabetic muscle cells, all three ligands stimulated glucose uptake similarly, whereas the sensitivity of glucose uptake was greatest in response to IGF-I and lower and equal for human insulin and insulin glargine. In diabetic muscle cells, the final responsiveness of glucose uptake was greatest for IGF-I and equivalent for human insulin and insulin glargine; sensitivities were the same as those for nondiabetic cells. Thymidine uptake into DNA was stimulated foremost by IGF-I, whereas human insulin and insulin glargine showed equivalent, but greatly reduced, sensitivities and potencies (<1% IGF-I). Stimulation of Akt phosphorylation was slightly more responsive to IGF-I compared with human insulin and insulin glargine, with sensitivities similar to glucose uptake stimulation. We conclude that in human skeletal muscle cells, insulin glargine is equivalent to human insulin for metabolic responses and does not display augmented mitogenic effects.




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri
Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease
Endocr. Rev., October 1, 2009; 30(6): 586 - 623.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. Shukla, J. Grisouard, V. Ehemann, A. Hermani, H. Enzmann, and D. Mayer
Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines
Endocr. Relat. Cancer, June 1, 2009; 16(2): 429 - 441.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. Erbel, C. Reers, V. W. Eckstein, J. Kleeff, M. W. Buchler, P. P. Nawroth, and R. A. Ritzel
Proliferation of Colo-357 Pancreatic Carcinoma Cells and Survival of Patients With Pancreatic Carcinoma Are Not Altered by Insulin Glargine
Diabetes Care, June 1, 2008; 31(6): 1105 - 1111.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
U Berg, T Gustafsson, C J Sundberg, L Kaijser, C Carlsson-Skwirut, and P Bang
Interstitial IGF-I in exercising skeletal muscle in women
Eur. J. Endocrinol., October 1, 2007; 157(4): 427 - 435.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
L. Jovanovic and D. J. Pettitt
Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes
Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. P. Ciaraldi, S. A. Phillips, L. Carter, V. Aroda, S. Mudaliar, and R. R. Henry
Effects of the Rapid-Acting Insulin Analog Glulisine on Cultured Human Skeletal Muscle Cells: Comparisons with Insulin and Insulin-Like Growth Factor I
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5551 - 5558.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. Mohn, M. Marcovecchio, F. Chiarelli, M. C. Haffner, M. P. Kufner, B. O. Boehm, and I. B. Hirsch
Insulin Analogues
N. Engl. J. Med., April 28, 2005; 352(17): 1822 - 1824.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. I. Chisalita and H. J. Arnqvist
Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E896 - E901.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. Castillo, M. Codina, M. L. Martinez, I. Navarro, and J. Gutierrez
Metabolic and mitogenic effects of IGF-I and insulin on muscle cells of rainbow trout
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R935 - R941.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Westerbacka, R. Bergholm, M. Tiikkainen, and H. Yki-Jarvinen
Glargine and Regular Human Insulin Similarly Acutely Enhance Endothelium-Dependent Vasodilatation in Normal Subjects
Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 320 - 324.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Vehkavaara and H. Yki-Jarvinen
3.5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes
Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 325 - 330.
[Abstract] [Full Text]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
B. Ahmad
Review: Pharmacology of insulin
The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
W. Niu, C. Huang, Z. Nawaz, M. Levy, R. Somwar, D. Li, P. J. Bilan, and A. Klip
Maturation of the Regulation of GLUT4 Activity by p38 MAPK during L6 Cell Myogenesis
J. Biol. Chem., May 9, 2003; 278(20): 17953 - 17962.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society